Clinical value of a screening tool for tumor predisposition syndromes in childhood cancer patients (TuPS)

MLA

Jan Loeffen, et al. “Clinical Value of a Screening Tool for Tumor Predisposition Syndromes in Childhood Cancer Patients (TuPS).” Familial Cancer, vol. 20, no. 4, Oct. 2021, pp. 263–71. EBSCOhost, https://doi.org/10.1007/s10689-021-00237-1.

APA

Jan Loeffen, Saskia M. J. Hopman, Natasha K. A. van Eijkelenburg, Cora M. Aalfs, Fonnet E. Bleeker, Lieke P.V. Berger, Peter Hammond, Floor A. M. Postema, Charlotte J. Dommering, Jakob K. Anninga, Janna A. Hol, Raoul C.M. Hennekam, Anja Wagner, Maran J. W. Olderode-Berends, Marry M. van den Heuvel-Eibrink, Tom G.W. Letteboer, Lisethe Meijer, Johannes H. M. Merks, Corianne A. J. M. de Borgie, & Wijnanda A. Kors. (2021). Clinical value of a screening tool for tumor predisposition syndromes in childhood cancer patients (TuPS). Familial Cancer, 20(4), 263–271. https://doi.org/10.1007/s10689-021-00237-1

Chicago

Jan Loeffen, Saskia M. J. Hopman, Natasha K. A. van Eijkelenburg, Cora M. Aalfs, Fonnet E. Bleeker, Lieke P.V. Berger, Peter Hammond, et al. 2021. “Clinical Value of a Screening Tool for Tumor Predisposition Syndromes in Childhood Cancer Patients (TuPS).” Familial Cancer 20 (4): 263–71. doi:10.1007/s10689-021-00237-1.